Breast Cancer
Latest News
Advertisement
Latest Videos
Podcasts
Advertisement
More News
96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial
ByNadia Harbeck, MD, PhD,Eleni Karapanagiotou,Fanny Le Du,Kevin Kalinsky, MD, MS,Shani Paluch-Shimon,Jasotha Sanmugarajah,Luis Costa,Einav Nili Gal-Yam,Joyce O’Shaughnessy, MD,Eriko Tokunaga,Sercan Aksoy,Rajnish Nagarkar,Brenda Grimes,Ran Jennifer Wei,Belen San Antonio,Katheryn Moreira,Hope S. Rugo, MD
97 monarchE: Evaluation of Prognostic and Predictive Value of Ki-67 Index Pre- and Post-Neoadjuvant Chemotherapy and Changes Following NAC
ByJose Angel Garcia Saenz,Stephen R.D. Johnston,Nadia Harbeck, MD, PhD,Peter A. Fasching,Qiang Liu,Sema Sezgin Goksu,Ivan Toledano,Daphne T.F. Tsoi,Dorte Nielsen,Patricia Xavier Santi,Norikazu Masuda,Yoon Sim Yap,Margaret Block,Maria Munoz Fernandez,Brenda R Grimes,Jennifer Wei,Deli Liu,Miguel Martin, MD, PhD
98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1
ByKomal L. Jhaveri,Dejan Juric,Antonio Giordano,Antoine Italiano,Gennaro Daniele,Jordi Rodón,Amita Patnaik, MD,Jorge Bartolomé,Anthony D. Elias, MD,Pamela N. Munster, MD,Patricia Lorusso, DO,Aixa Soyano,Maria de Miguel,Joyce O’Shaughnessy, MD,Robert Wesolowski,Giuseppe Curigliano,Tatiana Hernández,Aurélie Lombard,Shawn T. Estrem,Lin Du,Xiaofan Xu,Alberto J. Montero, MD, MBA, CPHQ
Sac-TMT demonstrated a significant improvement in PFS vs chemotherapy as first-line treatment for unresectable locally recurrent or metastatic TNBC.
The approval, based on the phase 3 TROPION-Breast02 trial, marks a significant shift in the first-line treatment of patients with mTNBC.
99 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
ByKomal L. Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Phillippe Aftimos,Cristina Saura,Joyce O’Shaughnessy, MD,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,Junichiro Watanabe,Elgene Lim, MBBS, FRACP, PhD,Juan Huang,Qingyuan Zhang,Antonio Llombart-Cussac,Chiun-Sheng Huang,Bhardwaj Desai,Xuejing Aimee Wang,Shanshan Cao,Francois Clement Bidard
A telephone-based weight loss intervention from the phase 3 BWEL trial improved physical function, fatigue, and social role outcomes vs health education alone in patients with stage II to III breast cancer and BMI of at least 27.
Jesus D. Anampa, MD, MS, discussed SEER database trends in chemotherapy use for older women with TBNC and explained the rationale for using breast cancer–free survival vs OS.
101 Patient-Reported Outcomes (PROs) in Patients With ER+, HER2- Advanced Breast Cancer (ABC) Treated with Imlunestrant, Investigator’s Choice Standard Endocrine Therapy, or Imlunestrant+Abemaciclib: Results From the Phase III EMBER-3 Trial
ByGiuseppe Curigliano,Joyce O'Shaughnessy, MD,François-Clément Bidard,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Lisa A. Carey, MD,Meena Okera,Everton Melo,Flora Zagouri,Manuel Ernesto Magallanes Maciel,Nuri Karadurmus,Shakeela Bahadur,Rebecca M Speck,Xuejing Aimee Wang,Suzanne Young,Komal L. Jhaveri,Nadia Harbeck, MD, PhD
102 Imlunestrant (imlu) With or Without Abemaciclib (abema) in Advanced Breast Cancer (ABC): Safety Analyses From the Phase III EMBER-3 Trial
ByJoyce O’Shaughnessy, MD,Francois Clement Bidard,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Philippe Aftimos,Cristina Saura,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,J A Garcia-Saenz,Maria Fernandez Abad,Larissa de Paula,Yeon Hee Park,Ozgur Ozyilkan,Maria Munoz,Sabrina Formentini,Emily Barrett,Shanshan Cao,Aarti Chawla,Komal L. Jhaveri
TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer
ByFrancois Clement Bidard,Michail Ignatiadis,Giuseppe Curigliano,Binghe Xu,Theresa Link,Yoichi Naito,Huiping Li,Madoka Iwase,Mark A. Taylor,Carlos H Barrios,Tomofumi Osako,Kevin Kalinsky, MD, MS,Antonio Giordano,Shom Goel, MD,Libero Santarpia,Jason Quan Gong,Kathrine C. Fernandez,Zhe Zhang,Hope S. Rugo, MD
Based on data from the DESTINY-Breast11 and DESTINY-Breast05 trials, the FDA has approved T-DXd as neoadjuvant and adjuvant treatment for patients with HER2-positive early breast cancer.
107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)
ByAdam M. Brufsky, MD, PhD,François-Clément Bidard,Erica L. Mayer, MD, MPH,Yeon Hee Park,Wolfgang Janni,Cynthia X. Ma, MD, PhD,Massimo Cristofanilli, MD,Giampaolo Bianchini,Kevin Kalinsky, MD, MS,Hiroji Iwata,Stephen Chia,Peter A. Fasching,Zbigniew Nowecki,Javier Pascual,Einav Nili Gal-Yam,Wei-Pang Chung,Seock-Ah Im,Alberto Zambelli,Florence Dalenc,Mafalda Oliveira,Steven Fox,Manuel Selvi Miralles,Christopher Morrow,Cynthia Huang Bartlett,Nicholas C. Turner, MD
109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR
ByDiana I. Lüftner,Rupert Bartsch,Urs Breitenstein,Christian Jackisch,Volkmar Mueller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Khalil Zaman,Michael Schwitter,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Lidia Perlova-Griff,Rachel Wuerstlein,Timo Schinköthe,Corinne Vannier,Nadia Harbeck, MD, PhD
110 Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)
ByJ. Gil-Gil,M. Ruíz-Borrego,E. Carrasco,Y. Izarzugaza,C. Martínez-Vila,E. Galve,B. López-Barajas,E. Adrover,T. Silovski,M. Valero-Arbizu,Á. Guerrero-Zotano,S. González-Santiago,M. Echarri,A. Cano-Jiménez,A. Vethencourt-Casado,M. De Laurentis,C. Bueno-Muiño,B. Adamo,R. Andrés,C. Villanueva,F. Rojo,M. Casas,P. Wilson,J. Suissa,V. Adams,M. Martin
112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
ByRebecca Dent, MD,Zhimin Shao,Peter Schmid, MD,Javier Cortés, MD,David W. Cescon,Shighira Saji,Kyung Hae Jung,Thomas Bachelot,Shouman Wang,Gul Basaran,Yee Soo Chae,Rofhiwa Mathiba,Shin-Cheh Chen,Agostina Stradella,Nicola Battelli,Naoki Niikura,Kechen Zhao,Petra Vukovic,Michah Maxwell,Tiffany Traina, MD, FASCO
TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
4
Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC
5